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SEDLIN AND PROSTAGLANDIN E2 
DEHYDROGENASE – INTERACTIONS AND 
IMPLICATIONS FOR SPONDYLOEPIPHYSEAL 
DYSPLASIA TARDA
ABSTRACT N° D020_2012 / GENOMIC DISORDERS
Cecilia WL Chan1, May MY Choi1, Caleb CY Chan1, Danny Chan1, Sidney SB Yu2, Kath-
ryn SE Cheah1 and Julian A Tanner1 1Department of Biochemistry, The University of Hong 
Kong 2School of Biomedical Sciences, The Chinese University of Hong Kong
Spondyloepiphyseal dysplasia tarda (SEDT) is a rare X-linked, late-onset skeletal disease. 
Affected individuals develop phenotypes in their early childhood, displaying barrel-shaped 
chests, vertebral bodies malformation, flattened disc spaces and premature osteoarthri-
tis in weight-bearing joints. The disease was found linked to the gene SEDL coding for 
the protein sedlin. Sedlin is one of the subunits of the TRAPP (Transport Protein Particle) 
complex, which is responsible for vesicle tethering during endoplasmic reticulum-to-golgi 
transport. Although sedlin is known to function in intracellular trafficking, the reason why 
mutations in a trafficking protein lead to a skeletal disease remains unknown. To address 
this, four missense mutations (D47Y, S73L, F83S and V130D) of sedlin observed in SEDT 
patients were studied. Except D47Y, the other three mutations cause proteosomal deg-
radation of sedlin in cultured cells, whereas the D47Y mutation had a minor effect on 
Bet3 binding to sedlin. Pull-down assay was performed to identify novel sedlin interact-
ing partners. 15-hydroxyprostaglandin dehydrogenase (PGDH) was pulled down and the 
interaction was confirmed in cell culture system. Sedlin activates PGDH activity in vitro. By 
confocal microscopy, sedlin was also found to colocalize with PGDH in the cytosol. PGDH 
catalyzes the degradation of prostaglandin E2, which affects cartilage and bone growth. 
Further investigation is ongoing to understand the function of sedlin and the mechanism 
of disease for SEDT. This work was support by Research Grants Council of Hong Kong Ad-
ministrative region (AoE/M-04/04).
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